15 / 56
•
XSG: 5,2 m. vs 3,8 m.; HR:0,77 (0,6-0,99); p=0.047
•
SG 6 meses: 41% vs 8%; SG 12 meses: 17% vs 11%
•
XSLP: 2,1 m vs 1,3 m; SLP 12 semanas: 40% vs 15%
Ramucirumab vs BSC: REGARD
Fuchs et al. Lancet 2014; 383:31
|
|
15 / 56
15 / 56
•
XSG: 5,2 m. vs 3,8 m.; HR:0,77 (0,6-0,99); p=0.047
•
SG 6 meses: 41% vs 8%; SG 12 meses: 17% vs 11%
•
XSLP: 2,1 m vs 1,3 m; SLP 12 semanas: 40% vs 15%
Ramucirumab vs BSC: REGARD
Fuchs et al. Lancet 2014; 383:31